Kissei Pharmaceutical Co., Ltd. (TYO:4547)

Japan flag Japan · Delayed Price · Currency is JPY
4,125.00
+10.00 (0.24%)
Jul 15, 2025, 3:30 PM JST
Market Cap 170.92B
Revenue (ttm) 88.33B
Net Income (ttm) 11.96B
Shares Out 41.44M
EPS (ttm) 274.20
PE Ratio 15.04
Forward PE 14.25
Dividend 120.00 (2.92%)
Ex-Dividend Date Sep 29, 2025
Volume 52,100
Average Volume 68,940
Open 4,130.00
Previous Close 4,115.00
Day's Range 4,095.00 - 4,145.00
52-Week Range 3,150.00 - 4,300.00
Beta -0.11
RSI 59.70
Earnings Date Jul 29, 2025

About Kissei Pharmaceutical

Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan. The company offers Kalogra tablets, for the treatment of ulcerative colitis; Tabuneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Minirin Melt OD tablets; Malizeb tablets; Tavaris tablets for the treatment of chronic idiopathic thrombocytopenic purpura; Beova tablets for the treatment of overactive bladder treatment; and Darbepoetin Alfa BS injection JCR for the treatment of renal a... [Read more]

Sector Healthcare
Founded 1946
Employees 1,778
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4547
Full Company Profile

Financial Performance

In 2024, Kissei Pharmaceutical's revenue was 88.33 billion, an increase of 16.87% compared to the previous year's 75.58 billion. Earnings were 11.96 billion, an increase of 7.18%.

Financial Statements

News

Rigel Reports First Quarter 2025 Financial Results and Provides Business Update

First quarter 2025 total revenue of approximately $53.3 million , which includes net product sales of $43.6 million and contract revenues from collaborations of $9.8 million Generated $11.4 million of...

2 months ago - Benzinga